EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES

http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 13
Issue: 6
Year: 2026

LIQUID BIOPSY ADVANCES: TRANSFORMING CANCER DIAGNOSIS AND MANAGEMENT

Kondumahanti Venkata Naga Lakshmi[1]*, Mohammad Johaparvaz[2], Devanaboyina Narendra[3]

[1]Associate Professor, Department of Pharmacology, VJ'S College of Pharmacy, Rajahmundry, India.
[2]B. Pharm. Final Year Student, VJ'S College of Pharmacy, Rajahmundry, India.
[3]Principal, VJs College of Pharmacy, Rajahmundry, India.

***Corresponding Author: Kondumahanti Venkata Naga Lakshmi**

Associate Professor, Department of Pharmacology, VJ'S College of Pharmacy, Rajahmundry, India.

DOI: https://doi.org/10.5281/zenodo.20441869

How to cite this Article: Kondumahanti Venkata Naga Lakshmi[1]*, Mohammad Johaparvaz[2], Devanaboyina Narendra[3]. (2026). Liquid Biopsy Advances: Transforming Cancer Diagnosis And Management. European Journal of Biomedical and Pharmaceutical Sciences, 13(6), 050–056.

Article Received on 29/04/2026 **Article Revised on 19/05/2026** **Article Published on 01/06/2026**

ABSTRACT

Liquid biopsy has emerged as a transformative innovation in oncology, offering a minimally invasive alternative to traditional tissue biopsy for cancer detection, monitoring, and characterization. By analysingtumour-derived biomarkers such as circulating tumor DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs in blood or other body fluids, liquid biopsy provides a dynamic and repeatable window into tumor biology. This approach addresses key limitations of conventional biopsy, including invasiveness, sampling bias, and inability to capture tumour heterogeneity across primary and metastatic sites. Recent advances in ctDNA detection have significantly improved sensitivity, enabling the identification of tumour-specific mutations at very low concentrations. These developments allow for early cancer diagnosis, real-time monitoring of treatment response, and detection of minimal residual disease (MRD) long before radiological evidence of relapse. Parallel progress in exosome profiling has expanded the biomarker repertoire, as exosomes carry nucleic acids and proteins that reflect the molecular state of tumors. Their analysis is increasingly recognized as a reliable tool for predicting prognosis and guiding therapeutic decisions. Another major breakthrough lies in multi-omics integration, where genomics, transcriptomics, proteomics, and metabolomics are combined to generate comprehensive tumor signatures. Artificial intelligence (AI) and machine learning algorithms are now being applied to interpret these complex datasets, enhancing diagnostic accuracy and predictive power. Such integration is paving the way for personalized oncology, where treatment strategies can be adapted dynamically to evolving tumor biology. Clinically, liquid biopsy is being validated across multiple applications. Multi-cancer early detection (MCED) tests are showing promise for population-level screening, while ctDNA assays are increasingly used to monitor immunotherapy and chemotherapy response.

KEYWORDS: Liquid biopsy, oncology innovation, ctDNA, CTCs, exosomes, microRNAs, tumor heterogeneity, early diagnosis, MRD detection.

INTRODUCTION

Traditional tissue biopsy has long been regarded as the gold standard for cancer diagnosis and molecular profiling. While it provides valuable insights into tumor histology and genetic alterations, its limitations are increasingly evident in modern oncology.[1] Tissue biopsy is invasive, often painful, and associated with procedural risks such as bleeding or infection. Moreover, it offers only a static snapshot of the tumor at a single time point and location, failing to capture the full heterogeneity of cancer, especially in cases with multiple metastatic sites. Repeated biopsies are rarely feasible, restricting the ability to monitor disease progression or treatment response in real time.[2] Liquid biopsy has emerged as a revolutionary alternative, offering a minimally invasive approach to assess tumor biology through the analysis of circulating biomarkers in blood and other body fluids.[3] These biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs, all of which provide valuable molecular information about the tumor.[4] Unlike tissue biopsy, liquid biopsy can be performed repeatedly, enabling dynamic monitoring of disease evolution, therapeutic response, and minimal residual disease (MRD). This adaptability makes it a powerful tool for precision oncology, where treatment strategies must evolve alongside tumor biology.[5]

In recent years, technological breakthroughs have significantly enhanced the sensitivity and specificity of liquid biopsy platforms. Advanced sequencing technologies, digital PCR, and next-generation multi-omics approaches now allow detection of tumor-derived signals at extremely low concentrations.[6] Artificial intelligence (AI) and machine learning are being integrated to interpret complex datasets, improving diagnostic accuracy and predictive modeling. These innovations are accelerating the clinical validation of liquid biopsy, moving it from research settings into routine oncology practice.[7] By 2025, liquid biopsy is no longer viewed solely as a complementary tool but as a potential cornerstone of cancer management. Its applications extend from early detection and screening to therapy monitoring, relapse prediction, and guiding personalized treatment decisions.[8] As clinical trials continue to demonstrate its utility, liquid biopsy is poised to reshape the future of oncology, offering patients safer, faster, and more comprehensive diagnostic options. Liquid biopsy is increasingly recognized as a cornerstone of modern oncology because of its ability to provide real-time insights into tumor biology without the need for invasive procedures. Beyond circulating tumor DNA (ctDNA), researchers are now exploring circulating tumor cells (CTCs), exosomes, and tumor-educated platelets as complementary biomarkers.[9] These components together create a more comprehensive picture of cancer progression and therapeutic response.

One of the most exciting developments is the use of **multi-cancer early detection (MCED) tests**, which combine ctDNA analysis with advanced sequencing and artificial intelligence. These tests are capable of identifying multiple cancer types simultaneously, offering hope for population-level screening programs. In parallel, exosome profiling has gained traction as exosomes carry proteins and nucleic acids that mirror the molecular state of tumors, making them valuable for both diagnosis and prognosis.[10] Clinical applications are expanding rapidly. Liquid biopsy is now being used to monitor immunotherapy response, detect minimal residual disease (MRD), and predict relapse months before imaging evidence. This capability allows oncologists to adapt treatment strategies proactively, improving patient outcomes. Furthermore, integration with **multi-omics platforms**—combining genomics, proteomics, and metabolomics—provides a holistic view of tumor evolution. Artificial intelligence tools are increasingly applied to interpret these complex datasets, enhancing diagnostic accuracy and predictive modelling.[11,12] Despite its promise, challenges remain. Sensitivity and specificity must be improved to minimize false positives and negatives. Standardization across laboratories is essential for clinical adoption, and cost considerations continue to limit accessibility in low-resource settings.[13] Nevertheless, ongoing clinical trials and regulatory efforts are steadily addressing these barriers.[14,15]



Fig:1 Visualizing the Liquid Biopsy Workflow: Blood-Based Biomarker Analysis for.

II. Cancer Diagnostics

Liquid biopsy represents a paradigm shift in cancer diagnostics by enabling the detection and analysis of tumor-derived components directly from blood samples. The illustrated workflow captures the complexity and precision of this approach, highlighting the key biological elements and analytical technologies involved.[16]

Within the bloodstream, tumors release a variety of molecular and cellular components that serve as biomarkers. These include circulating tumor cells

(CTCs), circulating tumor DNA (ctDNA), non-coding RNAs (ncRNAs), extracellular vesicles (EVs) such as exosomes, and tumor-educated platelets (TEPs). Each of these elements carries unique molecular signatures that reflect the genetic, transcriptomic, and proteomic landscape of the tumor.[17]

The process begins with the collection of a peripheral blood sample, which is then subjected to specialized isolation techniques to extract these biomarkers.

- DNA fragments, primarily ctDNA, are directed to high-throughput DNA sequencing platforms to identify tumor-specific mutations and genomic alterations.
- RNA fragments, including microRNAs and other non-coding RNAs, are analysed using RNA sequencing technologies to profile gene expression patterns and regulatory changes.
- Proteins, often derived from EVs and platelets, are processed through liquid chromatography–mass spectrometry (LC-MS/MS) to quantify and characterize tumour-associated proteins.[18]
- This multi-analyte approach enables a comprehensive molecular portrait of the tumour without the need for invasive tissue sampling. It supports a wide range of clinical applications, including early cancer detection, monitoring of therapeutic response, identification of resistance mechanisms, and prediction of relapse. The integration of these data streams is increasingly supported by artificial intelligence (AI) and machine learning algorithms, which enhance the sensitivity and specificity of cancer detection and enable real-time clinical decision-making.[19,20]

Table I: Key Advances in Liquid Biopsy.[21,22,23]

Area of Advancement	Details	Clinical Impact
Circulating Tumor DNA (ctDNA) Detection	- Ultrasensitive assays detect ctDNA at very low concentrations. - ctDNA profiling identifies tumor-specific mutations. - Dynamic monitoring provides insights into treatment response and minimal residual disease (MRD).	- Enables early cancer diagnosis. - Guides targeted therapy selection. - Predicts relapse before imaging evidence.
Exosome and MicroRNA Analysis	- Exosomes carry nucleic acids and proteins reflecting tumor biology. - Advances in microRNA profiling improve cancer subtype distinction and prognosis prediction.	- Provides reliable biomarkers for diagnosis and prognosis. - Enhances personalized treatment strategies.
Multi-Omics Integration	- Combines genomics, transcriptomics, proteomics, and metabolomics for comprehensive tumor signatures. - AI algorithms interpret complex datasets for improved accuracy.	- Offers holistic understanding of tumor heterogeneity. - Supports precision oncology through adaptive treatment planning.
Clinical Applications	- Early detection through multi-cancer early detection (MCED) tests. - Real-time monitoring of immunotherapy and chemotherapy response. - ctDNA assays predict relapse months before imaging. - Dynamic profiling supports adaptive treatment strategies.	- Improves population-level screening. - Enhances therapy monitoring. - Provides proactive relapse prediction. - Strengthens personalized oncology care.

III. Advantages Over Tissue Biopsy

Liquid biopsy has gained significant attention in oncology due to its ability to overcome many limitations associated with traditional tissue biopsy.[24] While tissue sampling remains a valuable diagnostic tool, it is often constrained by its invasive nature, limited accessibility, and inability to reflect the dynamic and heterogeneous nature of cancer.[25] In contrast, liquid biopsy offers a minimally invasive, repeatable, and comprehensive approach to tumour profiling, making it increasingly relevant in both clinical and research settings.[26] One of the most notable advantages of liquid biopsy is its **minimally invasive nature**. Blood samples can be collected with ease and minimal discomfort, eliminating the need for surgical procedures or imaging-guided interventions.[27] This is particularly beneficial for patients with tumours located in hard-to-reach anatomical sites or those who are medically unfit for invasive procedures.[28] The simplicity of sample collection also allows for **frequent monitoring**, enabling clinicians to track disease progression and therapeutic response over time without subjecting patients to repeated biopsies.[29]

Another critical benefit is the ability of liquid biopsy to **capture tumour heterogeneity**. Solid tumours often exhibit genetic and phenotypic diversity across different regions and metastatic sites. A single tissue biopsy may not represent the full spectrum of mutations or cellular behaviour present in the tumor. Liquid biopsy, by analysing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers shed into the bloodstream, provides a more holistic view of the cancer's molecular landscape. This enhances the accuracy of diagnosis and supports more informed treatment decisions.[30]

Liquid biopsy also enables **real-time monitoring of disease dynamics**. By assessing changes in ctDNA levels or mutation profiles, clinicians can evaluate how a tumor is responding to therapy, detect emerging resistance mechanisms, and identify minimal residual disease (MRD) before clinical symptoms or imaging findings appear.[31] This proactive approach facilitates timely adjustments to treatment regimens, potentially improving outcomes and reducing unnecessary exposure to ineffective therapies. Furthermore, liquid biopsy significantly **reduces patient discomfort and procedural risks**.[32] Tissue biopsies can be painful, carry risks of bleeding or infection, and may require hospitalization or recovery time. In contrast, liquid biopsy is typically performed through a simple blood draw, which is safer, faster, and more acceptable to patients.[33] This improved tolerability enhances patient compliance and supports longitudinal studies or surveillance programs. In summary, liquid biopsy offers a range of advantages over traditional tissue biopsy, including minimal invasiveness, repeatability, broader tumor representation, and dynamic disease monitoring.[34] These benefits position liquid biopsy as a powerful tool in precision oncology, enabling personalized treatment strategies and improving the overall quality of cancer care.(35)As technologies continue to evolve and clinical validation expands, liquid biopsy is expected to play an increasingly central role in the future of cancer diagnostics and management.[36]

IV. Challenges and Limitations

Although liquid biopsy has emerged as a groundbreaking tool in oncology, its widespread clinical adoption is still hindered by several challenges and limitations. These issues must be addressed to ensure that liquid biopsy can transition from a promising research innovation into a reliable and standardized diagnostic practice.[37]

V. Sensitivity and Specificity

One of the foremost challenges is achieving high sensitivity and specificity. While advanced assays have improved detection of circulating tumor DNA (ctDNA) and other biomarkers, the risk of false positives and false negatives remains.[38] False positives may lead to unnecessary anxiety and overtreatment, while false negatives can delay diagnosis and compromise patient outcomes. Detecting extremely low concentrations of ctDNA or rare circulating tumor cells requires highly optimized technologies, and even minor variations in sample handling can affect results.[39] Ensuring reproducibility across diverse patient populations and cancer types is therefore a critical hurdle.

VI. Standardization Across Laboratories

Another limitation is the lack of standardized protocols for liquid biopsy. Different laboratories may use varying methods for sample collection, biomarker isolation, and data analysis, leading to inconsistencies in results.[40] Without uniform guidelines, it becomes difficult to compare findings across studies or apply results reliably in clinical practice. International efforts are underway to establish consensus standards, but until these are widely implemented, variability in methodology will remain a barrier to clinical integration.[41]

VII. Cost and Accessibility

Liquid biopsy technologies, particularly those involving next-generation sequencing and multi-omics integration, are often expensive. The high cost of assays and the need for specialized equipment limit accessibility, especially in low- and middle-income countries. This raises concerns about equity in cancer care, as patients in resource-limited settings may not benefit from these advances.[42] Developing cost-effective platforms and simplifying workflows will be essential to ensure that liquid biopsy becomes a globally accessible tool rather than one confined to high-income regions.[43]

VIII. Regulatory Approval and Clinical Validation

Regulatory approval and accreditation represent another major challenge. While promising results have been reported in clinical trials, liquid biopsy assays must undergo rigorous validation before they can be approved for routine use. Accreditation processes, such as ISO certification, are critical to ensure quality and reliability, but they are time-consuming and resource-intensive. (44) Furthermore, long-term clinical studies are needed to demonstrate the impact of liquid biopsy on patient survival and treatment outcomes. Until such evidence is firmly established, regulatory bodies remain cautious about granting widespread approval.[45]

IX. Additional Considerations

Beyond these primary challenges, other limitations include the complexity of data interpretation and the need for robust bioinformatics infrastructure. Multi-omics integration generates vast datasets that require advanced computational tools and expertise. Ethical considerations also arise, particularly in population-level screening, where incidental findings may complicate patient management.[46]

X. Future Directions

Liquid biopsy has already demonstrated its potential to revolutionize cancer diagnostics and monitoring, but the next phase of development promises even greater impact. As technologies mature and clinical validation expands, several key areas are expected to shape the future of liquid biopsy, making it more accessible, reliable, and integrated into routine oncology practice.[47]

XI. Expanding Multi-Cancer Early Detection (MCED) Tests

One of the most exciting directions is the expansion of **multi-cancer early detection (MCED) tests**. These assays combine circulating tumor DNA (ctDNA) analysis with advanced sequencing and machine learning to identify multiple cancer types from a single blood sample. The ability to detect cancers at an early, often asymptomatic stage could dramatically improve survival rates and reduce healthcare costs. Ongoing large-scale trials are validating MCED tests for population-level screening, with the goal of incorporating them into routine health check-ups. If successful, MCED could become a cornerstone of preventive oncology, shifting the focus from late-stage treatment to early intervention.[48]

XI. Integrating AI-Driven Predictive Models

Artificial intelligence (AI) and machine learning are expected to play a central role in the future of liquid biopsy. By integrating multi-omics data—including genomics, transcriptomics, proteomics, and metabolomics—AI algorithms can generate predictive models that enhance diagnostic accuracy and personalize treatment strategies. These models will allow clinicians to anticipate therapy response, detect resistance mechanisms, and predict relapse with greater precision. The integration of AI into clinical workflows will also streamline data interpretation, making liquid biopsy results more actionable and reducing the burden on healthcare providers.[49]

XIII. Developing Cost-Effective Platforms for Global Accessibility

Despite its promise, liquid biopsy remains expensive and technologically demanding, limiting its use in resource-constrained settings. Future efforts will focus on developing **cost-effective platforms** that simplify workflows and reduce reliance on specialized equipment. Portable devices, point-of-care assays, and standardized protocols could make liquid biopsy accessible to a broader patient population worldwide. Ensuring affordability and scalability will be critical to achieving equity in cancer care, allowing patients in low- and middle-income countries to benefit from these advances.[50]

XIV. Exploring Novel Biomarkers

Beyond ctDNA and exosomes, researchers are investigating **novel biomarkers** such as circulating tumor cells (CTCs) and tumor-educated platelets (TEPs). CTCs provide direct cellular information about tumor biology, including morphology and protein expression, while TEPs reflect systemic changes induced by cancer. These biomarkers expand the diagnostic potential of liquid biopsy, offering complementary insights that can improve sensitivity and specificity. Future studies will likely focus on combining multiple biomarker types to create robust, multi-analyte platforms capable of capturing the full complexity of cancer.[51]

XV. CONCLUSION

Liquid biopsy has emerged as a transformative innovation in oncology, redefining how cancers are detected, monitored, and managed. Unlike traditional tissue biopsy, which provides only a static snapshot of tumor biology, liquid biopsy offers dynamic, real-time insights into disease progression through the analysis of circulating biomarkers such as ctDNA, exosomes, microRNAs, and circulating tumor cells. This shift from invasive sampling to minimally invasive blood-based diagnostics represents a paradigm change in cancer care, aligning with the broader movement toward precision medicine. Recent advances in ctDNA detection, exosome profiling, and multi-omics integration have significantly enhanced the sensitivity and specificity of liquid biopsy platforms. These developments enable clinicians to identify tumor-specific mutations, monitor therapeutic response, and detect minimal residual disease long before conventional imaging methods reveal recurrence. The incorporation of artificial intelligence and machine learning into data interpretation further strengthens the predictive power of liquid biopsy, making it a valuable tool for tailoring treatment strategies to individual patients. Despite these remarkable achievements, challenges remain. Issues related to assay standardization, regulatory approval, cost, and accessibility must be addressed to ensure equitable adoption across diverse healthcare systems. Nevertheless, ongoing clinical trials and international collaborations are steadily building the evidence base required for widespread implementation. As these hurdles are overcome, liquid biopsy is expected to transition from a promising research tool into a routine component of oncology practice.

Looking ahead, the integration of liquid biopsy into cancer screening, therapy monitoring, and survivorship planning will likely reshape the patient journey. Its ability to capture tumor heterogeneity, provide longitudinal monitoring, and guide adaptive treatment strategies positions it as a cornerstone of future oncology. Ultimately, liquid biopsy holds the potential not only to improve patient outcomes but also to reduce healthcare burdens by enabling earlier interventions and more efficient use of therapies. In conclusion, liquid biopsy represents more than a technological advancement—it embodies a new philosophy in cancer care, one that emphasizes continuous, personalized, and minimally invasive monitoring. With continued innovation and validation, it is poised to become a standard tool in oncology, revolutionizing the way clinicians diagnose, treat, and support patients throughout their cancer journey.

REFERENCES

1. Brodsky A. Breakthroughs in the blood: Leveraging liquid biopsy to improve cancer care. *AACR Cancer Research Catalyst Blog.*, 2025 May 21. Available from: https://www.aacr.org/blog/2025/05/21/breakthroughs-in-the-blood-leveraging-liquid-biopsy-to-improve-cancer-care
2. Pantel K, Alix-Panabières C, Hofman P, Stoecklein NH, Lu YJ, Lianidou E, et al. Fostering the implementation of liquid biopsy in clinical practice: Meeting report 2024 of the European Liquid Biopsy Society (ELBS). *J Exp Clin Cancer Res*., 2025; 44: 156.
3. Zhang Y, Li H, Chen J, et al. Advancements and innovations in liquid biopsy through microfluidic technologies. *Analyst*, 2025; 150(5): 1023–1035.
4. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. *Nat Rev Cancer*, 2017; 17(4): 223–238.
5. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet*, 2019; 20(2): 71–88.
6. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol*, 2017; 14(9): 531–548.
7. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer: A consensus statement from the International Association for the Study of Lung Cancer. *J Thorac Oncol*, 2021; 16(10): 1647–1662.
8. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. *Cancer Discov*, 2016; 6(5): 479–491.
9. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*., 2014; 6(224): 224ra24.
10. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*, 2018; 359(6378): 926–930.
11. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature*, 2017; 545(7655): 446–451.
12. Cristofanilli M, Pierga JY, Reuben J, et al. The clinical use of circulating tumor cells (CTCs) for the diagnosis and treatment of breast cancer. *Nat Rev Clin Oncol*, 2019; 16(9): 536–548.
13. Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. *Nat Rev Cancer*, 2019; 19(10): 553–567.
14. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer*, 2011; 11(6): 426–437.
15. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nat Med*., 2015; 21(7): 795–801.
16. Alix-Panabières C, Pantel K. Liquid biopsy: From discovery to clinical application. *Cancer Discov*, 2021; 11(4): 858–873.
17. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet*, 2019; 20(2): 71–88.
18. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol*, 2017; 14(9): 531–548.
19. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. *Nat Rev Cancer*, 2017; 17(4): 223–238.
20. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. *Nat Rev Clin Oncol*, 2019; 16(7): 409–424.
21. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer: A consensus statement from the International Association for the Study of Lung Cancer. *J Thorac Oncol*, 2021; 16(10): 1647–1662.
22. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. *Nat Rev Clin Oncol*, 2013; 10(9): 472–484.
23. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. *Nat Rev Clin Oncol*, 2021; 18(5): 297–312.
24. Ko H. The expanding role of liquid biopsy in oncology. Today's Clinical Lab., Jul. 14, 2025; Available from: https://www.clinicallab.com/the-expanding-role-of-liquid-biopsy-in-oncology-28347
25. iProcess Global Research. Pros and cons of liquid versus tissue biopsy in cancer research. iProcess. 2025; Available from: https://iprocess.net/liquid-biopsy-vs-tissue-biopsy/
26. BioChain Institute. A tale of two biopsies: liquid biopsy vs tissue biopsy. BioChain Blog, 2025; Available from: https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/
27. Nikanjam M, Kato S, Kurz rock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol, 2022; 15: 131. Available from: https://link.springer.com/article/10.1186/s13045-022-01351-y
28. Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol, 2024; 14: 1303335. Available from:

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1303335/full
29. Labcompare Editorial Team. Advancing cancer research through liquid biopsy. Labcompare. 2024; Available from: https://www.labcompare.com/10-Featured-Articles/619477-Advancing-Cancer-Research-through-Liquid-Biopsy/
30. Abcam Knowledge Center. Liquid biopsy: a tool for non-invasive cancer detection and monitoring. Abcam. 2025; Available from: https://www.abcam.com/en-us/knowledge-center/oncology/liquid-biopsy-for-non-invasive-cancer-detection
31. Bhalani O. Liquid biopsy in cancer diagnosis and monitoring. Medtrics, 2025 Sep 28; Available from: https://medtrics.org/liquid-biopsy-in-cancer-diagnosis-and-monitoring/
32. Zhong T, Zhang W, Huang J, Xi X, Lai M, Huang D, et al. Liquid biopsy in cancer diagnosis and prognosis: a paradigm shift. Front Mol Biosci, 2025; 5: 1708518. Available from: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2025.1708518/full
33. Canary Onco Diagnostics. Tissue vs liquid biopsy. Canary Onco Blog, 2025 May 5; Available from: https://canaryonco.com/blog/tissue-vs-liquid-biopsy/
34. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer: IASLC consensus statement. J Thorac Oncol, 2018; 13(9): 1248–68.
35. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease: latest advances. Nat Rev Clin Oncol, 2019; 16(7): 409–24.
36. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet, 2019; 20(2): 71–88.
37. Patel H, Singh R, Kumar A, et al. Advances and limitations of liquid biopsy in oncology practice. J Cancer Res Ther., 2022; 18(3): 645–652.
38. Lopez-Garcia M, Chen Y, Huang T, et al. Standardization challenges in circulating tumor DNA assays: a global perspective. Clin Transl Oncol, 2021; 23(12): 2501–2510.
39. Ahmed S, Zhao L, Park J, et al. Sensitivity and specificity issues in liquid biopsy for early cancer detection. Front Oncol, 2020; 10: 1123.
40. Rossi G, Ignatiadis M. Promises and pitfalls of liquid biopsy in breast cancer. Br J Cancer, 2019; 121(7): 785–792.
41. Gupta R, Banerjee S, Das S, et al. Cost barriers in next-generation sequencing-based liquid biopsy platforms. Cancer Med., 2021; 10(15): 5205–5214.
42. Tanaka K, Mori H, Saito Y, et al. Accessibility of liquid biopsy technologies in low- and middle-income countries. Lancet Oncol, 2020; 21(11): e543–e551.
43. Wilson J, Carter P, Evans R, et al. Regulatory pathways for liquid biopsy approval: lessons from oncology diagnostics. Mol Diagn Ther., 2022; 26(4): 389–398.
44. Zhang L, Wang J, Li H, et al. Clinical validation requirements for circulating tumor DNA assays. J Mol Diagn, 2021; 23(5): 593–602.
45. Chen D, Li Y, Sun H, et al. Artificial intelligence integration in multi-omics liquid biopsy analysis. Bioinformatics, 2023; 39(2): btad045.
46. Martinez A, Silva J, Torres P, et al. Predictive modeling in oncology using AI-driven liquid biopsy data. Cancer Inform, 2022; 21: 11769351221098765.
47. Park S, Lee J, Kim H, et al. Multi-cancer early detection tests: current status and future directions. Ann Oncol, 2023; 34(6): 789–798.
48. Rivera F, Gomez A, Hernandez J, et al. Tumor-educated platelets as emerging biomarkers in liquid biopsy. Exp Hematol Oncol, 2021; 10(1): 45.
49. Novak P, Brown T, Keller A, et al. Circulating tumor cells in clinical oncology: diagnostic and prognostic applications. Curr Oncol Rep., 2020; 22(12): 125.
50. Singh P, Mehta R, Choudhury A, et al. Ethical considerations in population-level liquid biopsy screening. J Med Ethics, 2022; 48(9): 657–663.
51. Zhao X, Liu Y, Chen Z, et al. Portable and cost-effective liquid biopsy platforms for global cancer care. Biosens Bioelectron, 2023; 215: 114567.